Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential to reduce treatment costs.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Chronic insomnia, REM sleep instability and emotional dysregulation
Risk factors for anxiety and depression
- Immune sensors
Dysfunctional signaling pathways in cardiomyocytes and their role in heart disease
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- Dementia
Recognize incipient progression and identify countermeasures
- Subtype-specific risks and implications for neurological care
Suicidal tendencies in dementia
- Study report: Hidradenitis suppurativa
Comparison of rifampicin monotherapy with clindamycin/rifampicin combination
- From symptom to diagnosis
Oncology – Prostate carcinoma
- Stress-hyperglycemia quotient and machine learning